Pfizer Inc. (NYSE:PFE) Shares Sold by Mirador Capital Partners LP

Mirador Capital Partners LP lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 88.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 9,051 shares of the biopharmaceutical company’s stock after selling 72,596 shares during the period. Mirador Capital Partners LP’s holdings in Pfizer were worth $251,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Chapin Davis Inc. boosted its stake in shares of Pfizer by 0.8% during the 1st quarter. Chapin Davis Inc. now owns 58,258 shares of the biopharmaceutical company’s stock worth $1,617,000 after acquiring an additional 459 shares in the last quarter. Oak Asset Management LLC boosted its position in Pfizer by 39.1% during the first quarter. Oak Asset Management LLC now owns 24,215 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 6,809 shares in the last quarter. Roberts Wealth Advisors LLC acquired a new stake in Pfizer in the first quarter valued at approximately $1,374,000. Barry Investment Advisors LLC increased its position in shares of Pfizer by 1.1% in the first quarter. Barry Investment Advisors LLC now owns 192,573 shares of the biopharmaceutical company’s stock valued at $5,344,000 after buying an additional 2,123 shares in the last quarter. Finally, SteelPeak Wealth LLC raised its stake in shares of Pfizer by 62.6% during the 1st quarter. SteelPeak Wealth LLC now owns 38,810 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 14,947 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, June 26th. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $35.54.

Pfizer Stock Up 0.9 %

NYSE PFE opened at $28.22 on Tuesday. The business’s fifty day simple moving average is $27.90 and its 200-day simple moving average is $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The firm has a market cap of $159.91 billion, a PE ratio of -470.25, a P/E/G ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 5.95%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.